Literature DB >> 16542287

Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis.

Juan Turnes1, Juan Carlos Garcia-Pagan, Juan G Abraldes, Manuel Hernandez-Guerra, Alessandra Dell'Era, Jaime Bosch.   

Abstract

OBJECTIVES: A reduction in hepatic venous pressure gradient (HVPG) of > or =20% of baseline or to < or =12 mmHg (responders) is associated with a reduced risk of first variceal bleeding. The aim of this study was to evaluate whether this protective effect is maintained in the long term and if it extends to other portal hypertension complications.
METHODS: Seventy-one cirrhotic patients with esophageal varices and without previous variceal bleeding who entered into a program of prophylactic pharmacological therapy and were followed for up to 8 yr were evaluated. All had two separate HVPG measurements, at baseline and after pharmacological therapy with propranolol +/- isosorbide mononitrate.
RESULTS: Forty-six patients were nonresponders and 25 were responders. Eight-year cumulative probability of being free of first variceal bleeding was higher in responders than in nonresponders (90% vs 45%, p= 0.026). The lack of hemodynamic response and low platelet count were the only independent predictors of first variceal bleeding. Additionally, reduction of HVPG was independently associated with a decreased risk of spontaneous bacterial peritonitis (SBP) or bacteremia. No significant differences in the development of ascites, hepatic encephalopathy, or survival were observed.
CONCLUSIONS: The hemodynamic response in cirrhotic patients is associated with a sustained reduction in the risk of first variceal bleeding over a long-term follow-up. Reduction of HVPG also correlate with a reduced risk of SBP or bacteremia.

Entities:  

Mesh:

Year:  2006        PMID: 16542287     DOI: 10.1111/j.1572-0241.2006.00453.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  48 in total

Review 1.  Hepatic venous pressure gradient: worth another look?

Authors:  Sameer Parikh
Journal:  Dig Dis Sci       Date:  2008-10-31       Impact factor: 3.199

2.  Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis.

Authors:  Lan Li; Chaohui Yu; Youming Li
Journal:  Can J Gastroenterol       Date:  2011-03       Impact factor: 3.522

Review 3.  Portal vein thrombosis in cirrhosis: Controversies and latest developments.

Authors:  Damian J Harding; M Thamara P R Perera; Frederick Chen; Simon Olliff; Dhiraj Tripathi
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

4.  Impact of splenic circulation: non-invasive microbubble-based assessment of portal hemodynamics.

Authors:  Taro Shimada; Hitoshi Maruyama; Takayuki Kondo; Tadashi Sekimoto; Masanori Takahashi; Osamu Yokosuka
Journal:  Eur Radiol       Date:  2014-11-01       Impact factor: 5.315

5.  Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window.

Authors:  Vincenzo La Mura; Giulia Tosetti; Massimo Primignani; Francesco Salerno
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

6.  Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study.

Authors:  Ki Tae Suk; Moon Young Kim; Dong Hun Park; Kyu Hong Kim; Ki Won Jo; Jin Hon Hong; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon; Soon Koo Baik
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

Review 7.  Pharmacologic prevention of variceal bleeding and rebleeding.

Authors:  Anna Baiges; Virginia Hernández-Gea; Jaime Bosch
Journal:  Hepatol Int       Date:  2017-12-05       Impact factor: 6.047

Review 8.  Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond.

Authors:  Horia Stefanescu; Bogdan Procopet
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.

Authors:  Manoj Kumar; Sumit Kainth; Ashok Choudhury; Rakhi Maiwall; Lalita G Mitra; Vandana Saluja; Prashant Mohan Agarwal; Saggere Muralikrishna Shasthry; Ankur Jindal; Ankit Bhardwaj; Guresh Kumar; Shiv K Sarin
Journal:  Hepatol Int       Date:  2019-09-20       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.